NCT01818986View on ClinicalTrials.gov

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 10, 2013

Primary Completion Date

December 20, 2019

Study Completion Date

May 25, 2021

Conditions
Metastatic Castrate-resistant Prostate CancermCRPC
Interventions
DRUG

Sipuleucel-T

RADIATION

Stereotactic Ablative Body Radiation

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT01818986 - Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) | Biotech Hunter | Biotech Hunter